We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.1B
AUM Growth
-$787M
Cap. Flow
+$233M
Cap. Flow %
2.56%
Top 10 Hldgs %
30.12%
Holding
189
New
31
Increased
28
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
IVVD icon
Invivyd
IVVD
+$200M
2
ZBH icon
Zimmer Biomet
ZBH
+$100M
3
BIIB icon
Biogen
BIIB
+$54.7M
4
HCA icon
HCA Healthcare
HCA
+$47.4M
5
MREO
Mereo BioPharma
MREO
+$45.7M

Top Sells

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$78.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$58.9M
3
NTRA icon
Natera
NTRA
+$55.6M
4
ELV icon
Elevance Health
ELV
+$48.9M
5
BSX icon
Boston Scientific
BSX
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.35%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
76
DELISTED
Verona Pharma
VRNA
$31.2M 0.34%
5,694,841
– –
LAB icon
77
Standard BioTools
LAB
$316M
$30.3M 0.33%
4,599,571
-62,300
-1% -$410K
HELP
78
Cybin Inc
HELP
$477M
$29.5M 0.32%
+353,872
New +$31M
CMMB
79
Chemomab Therapeutics
CMMB
$10.6M
$28.6M 0.31%
644,544
– –
CRIS icon
80
Curis
CRIS
$9.67M
$27.6M 0.3%
8,804
– –
MRSN
81
DELISTED
Mersana Therapeutics
MRSN
$27.2M 0.3%
115,554
+3,544
+3% +$1.04M
NSTG
82
DELISTED
NanoString Technologies, Inc.
NSTG
$26.7M 0.29%
556,000
– –
PCVX icon
83
Vaxcyte
PCVX
$7.72B
$26.2M 0.29%
1,034,665
+89,265
+9% +$2.16M
CGEM icon
84
Cullinan Oncology
CGEM
$1.07B
$25.9M 0.28%
1,146,145
– –
FUSN
85
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$25.5M 0.28%
3,224,770
– –
LENZ
86
LENZ Therapeutics
LENZ
$184M
$23.8M 0.26%
207,129
+49,085
+31% +$7.27M
IRON icon
87
Disc Medicine
IRON
$2.8B
$23.5M 0.26%
194,207
– –
AFIB
88
DELISTED
Acutus Medical Inc
AFIB
$23.4M 0.26%
2,648,386
-2,829,572
-52% -$37.2M
CLDX icon
89
Celldex Therapeutics
CLDX
$2.81B
$22.4M 0.25%
+414,300
New +$19.4M
OMIC
90
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$22.4M 0.25%
66,617
– –
OLMA icon
91
Olema Pharmaceuticals
OLMA
$986M
$22.3M 0.24%
807,792
– –
CTIC
92
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$22.2M 0.24%
7,520,600
– –
THC icon
93
Tenet Healthcare
THC
$22.2B
$20.7M 0.23%
+311,700
New +$22.1M
HARP
94
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$20.6M 0.23%
261,131
– –
GILD icon
95
Gilead Sciences
GILD
$166B
$20.1M 0.22%
287,600
– –
JNCE
96
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$19.7M 0.22%
2,655,600
+508,200
+24% +$3.15M
QURE icon
97
uniQure
QURE
$2.71B
$18.7M 0.21%
585,574
+114,400
+24% +$3.49M
VRCA icon
98
Verrica Pharmaceuticals
VRCA
$91.9M
$18.5M 0.2%
147,973
– –
SYBX
99
DELISTED
Synlogic
SYBX
$18.4M 0.2%
402,000
+155,556
+63% +$7.27M
NXTC icon
100
NextCure
NXTC
$21.2M
$18.3M 0.2%
225,918
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2021 Portfolio in Review

As of Q3 2021, OrbiMed held 189 positions worth $9.1B, down 8% from $9.89B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q3 2021 filing shows 31 new, 28 increased, 27 reduced and 17 closed positions. Its largest new stake was Invivyd: 5,383,500 shares worth $227M. The largest sale was Aurinia Pharmaceuticals, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology.

  • OrbiMed's largest Q3 2021 buy was Invivyd: 5,383,500 shares worth $227M.
  • OrbiMed added most to Biogen in Q3 2021, an estimated $54.7M increase.
  • OrbiMed's biggest Q3 2021 reduction was Natera, cutting an estimated $55.6M.
  • OrbiMed fully exited Aurinia Pharmaceuticals in Q3 2021, selling an estimated $78.7M.
  • OrbiMed's ten largest holdings make up 30% of its $9.1B portfolio in Q3 2021.
  • OrbiMed opened 31 new positions and closed 17 in Q3 2021.
  • OrbiMed's portfolio value fell 8% quarter-over-quarter to $9.1B.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.